Solid oral preparation containing ropinirole and preparation method thereof
By optimizing the formulation of solid oral preparation of ropinirole, combining drug active ingredients, disintegrants and lubricants, the production process is simplified and the problem of complex and costly preparation of existing ropinirole sustained release tablets is solved. Affordable and accessible treatment options are achieved and release characteristics similar to those of the three-layer tablets are maintained.
Patent Information
- Application Number
- CN202411129280.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-12
AI Technical Summary
The existing ropinirole sustained release tablets have complex and high cost preparation processes, making it difficult to provide an economical and accessible therapeutic option.
By optimizing the formulation, a solid oral preparation containing ropinirole is developed, using a combination of pharmaceutical active ingredients, disintegrants, gelling agents and fillers, combined with glidants and lubricants, simplifying the production process and achieving three Laminated sustained-release tablets have similar release characteristics.
In vitro release characteristics similar to traditional three-layer tablet sustained-release tablets are achieved, while simplifying the production process and reducing costs, providing patients with a more economical and accessible treatment option.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of pharmaceutical preparations, and in particular to a solid oral preparation containing ropinirole and a preparation method thereof. Background Art
[0002] Ropinirole is a dopamine receptor agonist commonly used to treat Parkinson's disease and restless legs syndrome. Oral solid dosage forms are one of the most common dosage forms of ropinirole, which can include the following types: regular tablets, extended-release tablets, and controlled-release tablets.
[0003] Sustained-release tablets are designed to prolong the release time of drugs in the body, thereby reducing the number of times the drug is taken. Parkinson's patients have difficulty in moving, and the development of ropinirole sustained-release tablets can help improve patient compliance and have important clinical value.
[0004] At present, the ropinirole sustained-release tablets used in clinical practice are three-layer tablets, with the middle layer being the drug-containing layer and the upper and lower layers being blank layers. This layered design can control the drug release area, thereby achieving a sustained-release effect. However, the preparation process of the three-layer tablet is complicated and requires a matching three-layer tablet press, resulting in a high production cost.
[0005] In order to provide patients with a more economical and accessible treatment option, it is necessary to develop a sustained-release tablet of ropinirole that does not require complex equipment and production processes. Summary of the invention
[0006] Based on this, one or more embodiments of the present application provide a solid oral preparation containing ropinirole and a preparation method thereof. The solid oral preparation of the present application has a release characteristic similar to that of a three-layer tablet, and the production process is simple and the cost is low.
[0007] The technical solution of this application includes the following contents:
[0008] A solid oral preparation containing ropinirole, comprising a pharmaceutically active ingredient, a disintegrant, a gelling agent and a filler;
[0009] The pharmaceutically active ingredient comprises at least one of ropinirole, a pharmaceutically acceptable salt of ropinirole and a ropinirole inclusion compound;
[0010] The rotational viscosity of a 2% aqueous solution of the gelling agent at 25° C. is 7023 cp to 115260 cp;
[0011] The disintegrant comprises at least one of sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone and low-substituted hydroxypropyl cellulose.
[0012] Optionally, the gelling agent is selected from at least one of hydroxypropyl methylcellulose HPMCK100M, hydroxypropyl cellulose HPC HF and polyoxyethylene PEO WSR303.
[0013] Optionally, the type of cross-linked polyvinylpyrrolidone in the disintegrant includes XL-10 type, and the type of low-substituted hydroxypropyl cellulose includes L-HPC 32 type.
[0014] Optionally, the solid oral preparation comprises, by weight percentage: 0.4% to 0.5% of the active pharmaceutical ingredient, 8.3% to 25% of the disintegrant, 55% to 75% of the gelling agent and 8% to 20% of the filler.
[0015] Furthermore, the solid oral preparation also includes at least one of a glidant and a lubricant.
[0016] Optionally, the solid oral preparation comprises, by weight percentage: 0.4% to 0.5% of the active pharmaceutical ingredient, 8.3% to 25% of the disintegrant, 55% to 75% of the gelling agent, 8% to 20% of the filler, 0.4% to 0.6% of the glidant and 10% to 12% of the lubricant.
[0017] Optionally, the lubricant includes a first lubricant and a second lubricant;
[0018] The weight ratio of the first lubricant to the second lubricant is (8-12):1;
[0019] The first lubricant comprises at least one of hydrogenated castor oil, glyceryl behenate and sodium stearyl fumarate;
[0020] The second lubricant includes at least one of magnesium stearate, sodium stearate, calcium stearate and stearic acid.
[0021] Furthermore, the solid oral preparation is in a single phase.
[0022] A method for preparing the solid oral preparation described above comprises the following steps:
[0023] The filler, a part of the gelling agent and the active pharmaceutical ingredient are mixed, and then the remaining part of the gelling agent and the disintegrant are added and mixed, and tableting is performed.
[0024] Optionally, the method for preparing the solid oral preparation comprises the following steps:
[0025] The filler, a portion of the gelling agent and the active pharmaceutical ingredient are mixed, and then the remaining portion of the gelling agent, the disintegrant, the glidant and the first lubricant are added and mixed, and then the second lubricant is added and mixed, and tableting is performed.
[0026] This application develops a solid oral preparation containing ropinirole through the optimization design of the preparation formula. The solid oral preparation has similar in vitro release characteristics to traditional three-layer sustained-release tablets. At the same time, it simplifies the production process, lowers the threshold for industrialization, and provides patients with a more economical and accessible treatment option. DETAILED DESCRIPTION
[0027] The present application will be further described below in conjunction with the embodiments and examples. It should be understood that these examples are only used to illustrate the present application and are not intended to limit the scope of the present application. In addition, it should be understood that after reading the content taught in the present application, those skilled in the art may make various changes or modifications to the present application, and these equivalent forms also fall within the protection scope of the claims attached to the present application.
[0028] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application belongs. The terms used herein in the specification of this application are only for the purpose of describing specific embodiments and are not intended to limit this application.
[0029] the term:
[0030] Unless otherwise specified or incompatible herewith, the terms and phrases used herein shall have the following meanings:
[0031] The terms "and / or", "or / and", and "and / or" used in this article have a selection scope that includes any one of two or more related listed items, and also includes any and all combinations of the related listed items, said any and all combinations including any two related listed items, any more related listed items, or a combination of all related listed items.
[0032] In the present application, "further" and the like are used for descriptive purposes to indicate differences in content, but should not be construed as limiting the scope of protection of the present application.
[0033] In the present application, the technical features described in an open manner include closed technical solutions composed of the listed features, and also include open technical solutions containing the listed features.
[0034] In this application, when it comes to numerical intervals (i.e., numerical ranges), unless otherwise specified, the optional numerical distribution is considered continuous within the above numerical interval, and includes the two numerical endpoints (i.e., the minimum and maximum values) of the numerical range, and each numerical value between the two numerical endpoints. Unless otherwise specified, when the numerical interval only refers to integers within the numerical interval, it includes the two endpoint integers of the numerical range, and each integer between the two endpoints. In addition, when multiple ranges are provided to describe features or characteristics, these ranges can be combined. In other words, unless otherwise specified, the ranges disclosed herein should be understood to include any and all subranges included therein.
[0035] In the present application, weight may be μg, mg, g, kg or other mass units known in the chemical industry.
[0036] In the present application, the particle size involved refers to the average particle size unless otherwise specified.
[0037] In one aspect of the present application, a solid oral preparation containing ropinirole is provided. The solid oral preparation of the present application has a release characteristic similar to that of a traditional three-layer sustained-release tablet, and the production process is simple and the cost is low.
[0038] In one embodiment, the solid oral dosage form containing ropinirole comprises a pharmaceutically active ingredient, a disintegrant, a gelling agent and a filler;
[0039] The active pharmaceutical ingredient comprises at least one of ropinirole, a pharmaceutically acceptable salt of ropinirole and a ropinirole inclusion compound;
[0040] The rotational viscosity of a 2% aqueous solution of the gelling agent at 25°C is 7023cp~115260cp;
[0041] The disintegrant includes at least one of sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone and low-substituted hydroxypropyl cellulose.
[0042] Optionally, the gelling agent is selected from hydroxypropyl methylcellulose HPMCK100M, hydroxypropyl cellulose HPC HF or polyoxyethylene PEO WSR303, preferably hydroxypropyl methylcellulose HPMCK100M.
[0043] Optionally, the type of cross-linked polyvinylpyrrolidone in the disintegrant includes XL-10 type, and the type of low-substituted hydroxypropyl cellulose includes L-HPC 32 type.
[0044] Optionally, the gelling agent is selected from hydroxypropylmethylcellulose HPMCK100M, hydroxypropylcellulose HPC HF or polyoxyethylene PEO WSR303, and the disintegrant is selected from sodium carboxymethylcellulose, XL-10 type cross-linked polyvinylpyrrolidone or L-HPC 32 type low-substituted hydroxypropylcellulose.
[0045] Furthermore, the solid oral preparation of the present application comprises, by weight percentage: 0.4% to 0.5% of a pharmaceutically active ingredient, 8.3% to 25% of a disintegrant, 55% to 75% of a gelling agent and 8% to 20% of a filler.
[0046] In one embodiment, based on 100% by weight of the solid oral preparation, the weight proportions of each component are as follows: active ingredient 0.4% to 0.5%, with exemplary weight proportions of 0.4%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, and 0.5%; disintegrant 8.3% to 25%, with exemplary weight proportions of 8.3%, 8.5%, 9%, 10%, 12%, 15%, 18%, 20%, 22%, 24%, and 25%; gelling agent 55% to 75%, with exemplary weight proportions of 55%, 58%, 60%, 62%, 65%, 68%, 70%, 72%, and 75%; filler 8% to 20%, with exemplary weight proportions of 8%, 10%, 12%, 15%, 18%, and 20%.
[0047] Optionally, the solid oral preparation of the present application further comprises at least one of a glidant and a lubricant.
[0048] Optionally, glidants include some materials commonly used in pharmaceutical preparations that can improve powder fluidity and reduce adhesion, such as microcrystalline cellulose, cross-linked sodium carboxymethyl cellulose, silicates, calcium stearate, magnesium stearate, povidone, lactose, talc, polyethylene glycol, hydrogenated vegetable oil, titanium dioxide and nano-silicon.
[0049] Optionally, lubricants include some materials commonly used in pharmaceutical preparations that can reduce the friction of particles or powders during processing and prevent powders from adhering to equipment, such as magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oil, polyethylene glycol, glycerin, talc, silicon dioxide, sodium lauryl sulfate, polysorbate, paraffin and microcrystalline wax.
[0050] Optionally, the lubricant includes a first lubricant and a second lubricant;
[0051] The weight ratio of the first lubricant to the second lubricant is (8-12):1;
[0052] The first lubricant includes at least one of hydrogenated castor oil, glyceryl behenate and sodium stearyl fumarate;
[0053] The second lubricant includes at least one of magnesium stearate, sodium stearate, calcium stearate and stearic acid.
[0054] The use of two different types of lubricants can better reduce friction and prevent adhesion in different steps.
[0055] Furthermore, the solid oral preparation of the present application comprises, by weight percentage: 0.4% to 0.5% of a pharmaceutically active ingredient, 8.3% to 25% of a disintegrant, 55% to 75% of a gelling agent, 8% to 20% of a filler, 0.4% to 0.6% of a glidant and 10% to 12% of a lubricant.
[0056] In one embodiment, based on 100% by weight of the solid oral preparation, the weight proportions of the components are as follows: 0.4% to 0.5% of the active pharmaceutical ingredient, with the weight proportions of 0.4%, 0.41%, 0.42%, 0.43%, 0.44%, 0.45%, 0.46%, 0.47%, 0.48%, 0.49%, 0.5% for example; 8.3% to 25% of the disintegrant, with the weight proportions of 8.3%, 8.5%, 9%, 10%, 12%, 15%, 18%, 20%, 22%, 24%, 25% for example; 55% to 75% of the gelling agent, with the weight proportion of 55% for example , 58%, 60%, 62%, 65%, 68%, 70%, 72%, 75%; filler 8%~20%, for example 8%, 10%, 12%, 15%, 18%, 20% by weight; glidant 0.4%~0.6%, for example 0.4%, 0.42%, 0.45%, 0.48%, 0.5%, 0.52%, 0.55%, 0.58%, 0.6%; lubricant 10%~12%, for example 10%, 10.2%, 10.5%, 10.8%, 11%, 11.2%, 11.5%, 11.8%, 12%.
[0057] In one embodiment, the weight ratio of the gelling agent to the disintegrant is (6-8):1, for example 6:1, 6.5:1, 7:1, 7.5:1, 8:1, etc.
[0058] In one embodiment, the solid oral preparation of the present application is in a single phase. Herein, a single phase means that all components in the medicament are present in the same phase without phase separation or stratification. Further, the solid oral preparation of the present application is in a homogeneous state. Herein, a homogeneous state means that the medicament presents a homogeneous form in which all components are uniformly mixed at the molecular or microscopic level.
[0059] In another aspect of the present application, a method for preparing a solid oral preparation is provided, which can be used to prepare the solid oral preparation containing ropinirole described in any of the above technical solutions, and the preparation method comprises the following steps:
[0060] The filler, a part of the gelling agent and the active pharmaceutical ingredient are mixed, and then the remaining part of the gelling agent and the disintegrant are added and mixed, and tableting is performed.
[0061] In one embodiment, the method for preparing the solid oral dosage form comprises the following steps:
[0062] mixing a filler, a portion of a gelling agent, and a pharmaceutically active ingredient to obtain a first mixture;
[0063] The remaining part of the gelling agent and the disintegrant are added to the first mixture and mixed to obtain a second mixture; the second mixture is tableted to obtain a solid oral preparation.
[0064] Optionally, in one embodiment, the raw materials for preparing the solid oral preparation also contain a glidant and a lubricant. In this case, after adding the remaining part of the gelling agent and the disintegrant to the first mixture and mixing, the glidant and the lubricant are also added and mixed to obtain a second mixture.
[0065] Optionally, in one embodiment, the lubricant includes a first lubricant and a second lubricant. In this case, the remaining portion of the gelling agent and the disintegrant are added to the first mixture and mixed, then the glidant and the first lubricant are added and mixed, and then the second lubricant is added and mixed to obtain the second mixture.
[0066] The meanings of lubricants and glidants refer to the definitions of lubricants and glidants described in any of the above technical solutions.
[0067] This application develops a solid oral preparation containing ropinirole through the optimization design of the preparation formula. The solid oral preparation has similar in vitro release characteristics to traditional three-layer sustained-release tablets. At the same time, it simplifies the production process, lowers the threshold for industrialization, and provides patients with a more economical and accessible treatment option.
[0068] The following are some specific embodiments.
[0069] For experimental parameters not specified in the following specific embodiments, reference is made to the instructions given in the present application document, and reference may also be made to experimental manuals in the art or other experimental methods known in the art, or to experimental conditions recommended by manufacturers.
[0070] The raw materials and reagents involved in the following specific examples can be obtained from commercial sources, or can be prepared by those skilled in the art according to known methods.
[0071] The sources of some raw materials are provided below. The viscometer is a NDJ-1 type rotary viscometer, the rotor speed is 20 rpm, the concentration of the material aqueous solution is 2% w / w, and the temperature is 25±2.5°C.
[0072] HPMC K100M is manufactured by Dow Chemical of the United States; the viscosity is 115260cp;
[0073] The manufacturer of PEO WSR303 is Dow Chemical of the United States; the viscosity is 38950cp;
[0074] HPC HF manufacturer is Ashland, USA; viscosity is 7023cp;
[0075] The manufacturer of HEC 100M is Ashland, USA, and the viscosity is 5329cp.
[0076] The manufacturer of cross-linked sodium carboxymethyl cellulose is JRS of Germany;
[0077] The manufacturer of cross-linked polyvinylpyrrolidone XL-10 is Ashland Corporation of the United States;
[0078] The manufacturer of L-HPC 32 is Shin-Etsu Chemical Co., Ltd. of Japan; the model is L-HPC 32.
[0079] Example 1
[0080] This example provides a method for preparing solid oral preparations F01 to F06 containing ropinirole. The raw materials and their amounts are shown in Table 1. The preparation steps are as follows:
[0081] 1. Sieve the prescribed amount of lactose monohydrate and 50% of the gelling agent through a 30-mesh sieve, place in a PE bag and mix manually for 5 minutes.
[0082] 2. Add the prescribed amount of active ingredients to the mixture in step 1, mix manually for 5 minutes, and pass through a 30-mesh sieve.
[0083] 3. Add the remaining 50% of the prescribed amount of gelling agent, disintegrant, glidant and lubricant hydrogenated castor oil to the mixture in step 2 after passing through a 30-mesh sieve, and mix manually for 15 minutes.
[0084] 4. Pass the lubricant magnesium stearate through a 30-mesh sieve, add it to the mixture in step 4, and mix manually for 5 minutes.
[0085] 5. Add the mixture obtained in step 4 to a rotary tablet press for tableting, and the tablet hardness ranges from 80N to 140N.
[0086] Table 1 Formulations of solid oral dosage forms F01 to F06 containing ropinirole
[0087]
[0088] In Table 1, the unit of each numerical value is mg, and “-” represents that the added amount of the item is 0, and 2 mg of ropinirole corresponds to 2.28 mg of ropinirole hydrochloride.
[0089] Example 2
[0090] This example provides a method for preparing solid oral preparations F07 to F12 containing ropinirole. The raw materials and their amounts are shown in Table 2. The preparation steps are as follows:
[0091] 1. Sieve the prescribed amount of lactose monohydrate and 50% of the gelling agent through a 30-mesh sieve, place in a PE bag and mix manually for 5 minutes.
[0092] 2. Add the prescribed amount of active ingredients to the mixture in step 1, mix manually for 5 minutes, and pass through a 30-mesh sieve.
[0093] 3. Add the remaining 50% of the prescribed amount of gelling agent, disintegrant, glidant and lubricant hydrogenated castor oil to the mixture in step 2 after passing through a 30-mesh sieve, and mix manually for 15 minutes.
[0094] 4. Pass the lubricant magnesium stearate through a 30-mesh sieve, add it to the mixture in step 4, and mix manually for 5 minutes.
[0095] 5. Add the mixture obtained in step 4 to a rotary tablet press for tableting, and the tablet hardness ranges from 80N to 140N.
[0096] Table 2 Formulations of solid oral preparations F07 to F12 containing ropinirole
[0097]
[0098] In Table 2, the unit of each numerical value is mg, and ropinirole 2 mg and 12 mg correspond to ropinirole hydrochloride 2.28 mg and 13.68 mg.
[0099] 2. In vitro drug release experiment
[0100] This section is the statistical results of in vitro release experiments on the solid preparations of various embodiments and comparative examples.
[0101] (1) The statistical results of the release data of F01~F06 are shown in Table 3.
[0102] Table 3 Release results of F01~F06 (pH 4.5 buffer, 900 ml, paddle method + sedimentation, 100 rpm)
[0103]
[0104] It can be found from Table 3 that F01, F02 and F03 use HPMC K100M, HPC HF and PEO WSR303 as gelling agents, respectively, with the prescription ratios of 65%, 75% and 75%, respectively. The prepared single-layer sustained-release tablets and the reference three-layer sustained-release tablets have similar release results in the pH 4.5 release medium, and the F2 value is greater than 50. However, when F04 uses HEC 100M as the gelling agent, the gel skeleton breaks and the gel strength is insufficient, resulting in burst release.
[0105] F01, F05 and F06 used sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone XL-10 and L-HPC 32 as disintegrants, respectively, to increase the gel volume after hydration. The prepared single-layer sustained-release tablets showed similar release results in the pH 4.5 release medium compared with the reference three-layer sustained-release tablets, and the F2 value was greater than 50.
[0106] (2) The statistical results of the release data of F07~F12 are shown in Table 4.
[0107] Table 4 Release results of F07~F12 (pH 4.5 buffer, 900ml, paddle method + settler, 100rpm)
[0108]
[0109] According to Table 4, the gelling agent ratio of F07~F09 is 55%~75%, and the prepared single-layer sustained-release tablets have similar in vitro release curves compared with the reference three-layer sustained-release tablets, and the F2 value is greater than 50. The disintegrant ratio of F10 and F11 is 8.3%~25%, and the prepared single-layer sustained-release tablets have similar in vitro release curves compared with the reference three-layer sustained-release tablets, and the F2 value is greater than 50. F07 and F12 correspond to different ropinirole specifications (specifications are 2mg and 12mg, respectively), and the two have the same tablet weight. The in vitro release curves are similar to those of the reference three-layer sustained-release tablets, and the F2 value is greater than 50.
[0110] The technical features of the above-mentioned implementation modes and examples can be combined in any appropriate manner. To make the description concise, not all possible combinations of the technical features in the above-mentioned implementation modes and examples are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.
[0111] The above-described embodiments only express several implementation methods of the present application, but they cannot be understood as limiting the scope of the patent application. It should be pointed out that, for those of ordinary skill in the art, without departing from the concept of the present application, several variations and improvements can also be made, which all belong to the protection scope of the present application. In addition, it should be understood that after reading the above-mentioned teaching content of the present application, those skilled in the art can make various changes or modifications to the present application, and the equivalent forms obtained also fall within the protection scope of the present application. It should also be understood that the technical solutions obtained by those skilled in the art on the basis of the technical solutions provided in the present application through logical analysis, reasoning or limited experiments are all within the protection scope of the claims attached to the present application. Therefore, the protection scope of the patent of the present application shall be based on the attached claims, and the description can be used to interpret the content of the claims.
Claims
1. A solid oral preparation containing ropinirole, characterized in that: Includes active pharmaceutical ingredients, disintegrants, gelling agents and fillers; The pharmaceutically active ingredient comprises at least one of ropinirole, a pharmaceutically acceptable salt of ropinirole and a ropinirole inclusion compound; The rotational viscosity of a 2% aqueous solution of the gelling agent at 25° C. is 7023 cp to 115260 cp; The disintegrant comprises at least one of sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone and low-substituted hydroxypropyl cellulose.
2. The solid oral preparation according to claim 1, characterized in that The gelling agent is selected from at least one of hydroxypropyl methylcellulose HPMCK100M, hydroxypropyl cellulose HPC HF and polyoxyethylene PEO WSR303.
3. The solid oral preparation according to claim 1, characterized in that The type of cross-linked polyvinylpyrrolidone in the disintegrant includes XL-10 type, and the type of low-substituted hydroxypropyl cellulose includes L-HPC 32 type.
4. The solid oral preparation according to any one of claims 1 to 3, characterized in that In terms of weight percentage, the composition comprises: 0.4% to 0.5% of the active pharmaceutical ingredient, 8.3% to 25% of the disintegrant, 55% to 75% of the gelling agent and 8% to 20% of the filler.
5. The solid oral preparation according to claim 1, characterized in that: Also included is at least one of a glidant and a lubricant.
6. The solid oral preparation according to claim 5, characterized in that: In terms of weight percentage, the composition comprises: 0.4% to 0.5% of the active pharmaceutical ingredient, 8.3% to 25% of the disintegrant, 55% to 75% of the gelling agent, 8% to 20% of the filler, 0.4% to 0.6% of the glidant and 10% to 12% of the lubricant.
7. The solid oral preparation according to claim 5 or 6, characterized in that: The lubricant includes a first lubricant and a second lubricant; The weight ratio of the first lubricant to the second lubricant is (8-12):1; The first lubricant comprises at least one of hydrogenated castor oil, glyceryl behenate and sodium stearyl fumarate; The second lubricant includes at least one of magnesium stearate, sodium stearate, calcium stearate and stearic acid.
8. The solid oral preparation according to any one of claims 1 to 3, 5 to 6, characterized in that The solid oral preparation is in a single phase.
9. A method for preparing a solid oral preparation according to any one of claims 1 to 8, characterized in that: The steps include: The filler, a part of the gelling agent and the active pharmaceutical ingredient are mixed, and then the remaining part of the gelling agent and the disintegrant are added and mixed, and tableting is performed.
10. A method for preparing a solid oral preparation according to any one of claims 7 to 8, characterized in that: The steps include: The filler, a portion of the gelling agent and the active pharmaceutical ingredient are mixed, and then the remaining portion of the gelling agent, the disintegrant, the glidant and the first lubricant are added and mixed, and then the second lubricant is added and mixed, and tableting is performed.
